Marvell Technology (MRVL.US)'s plan to acquire Lumentum (LITE.US) for a massive $115 billion to strengthen its AI ambitions has received a lukewarm initial reception from experts who bet on merger transactions.
According to multiple merger arbitrage specialists, the implied probability of the deal closing hovers at only around 50%, reflecting market skepticism about whether these two companies can complete one of the largest technology deals in history.
The sell-off in both stocks has caused Lumentum's share price to trade at a significant discount to Marvell's all-stock offer, while that offer itself has also shrunk. Since media first reported the potential merger late last month, Marvell has fallen nearly 40%, while Lumentum has dropped about 35%.
Investors are questioning the economics of the deal, and these doubts have been further amplified as a broader reassessment of AI trades triggered a stock market rout last week. As of Monday, a 14% spread existed between Lumentum's share price and Marvell's offer — a notable gap that reflects the scale and risk of the transaction. Even as tech stocks rose that day, the gap persisted.
Investors were already wary of the long wait and potentially complex regulatory review — the deal is not expected to close until 2028. Recent market turbulence has magnified these concerns, exposing the risks of an all-stock transaction whose strategic logic rests largely on the premise of continued growth in AI data center and connectivity spending.
Cabot Henderson, an event-driven strategy specialist at Jones Trading, said, "A deal that drags on this long, paired with an AI cycle moving at such a rapid pace, is really hard to calibrate; and when it's seen as a signal of a market top, it's never a good sign."
The $115 Billion AI Deal Faces Market Skepticism
Admittedly, it is not unusual for massive deals to initially encounter negative market reactions before investors digest the terms and eventually embrace their strategic logic. But Henderson noted that the magnitude of this stock price swing far exceeds ordinary nervousness.
Shareholder votes at both companies will be the near-term hurdle for the deal. Marvell's investors need to be convinced that the chipmaker is acquiring a critical piece of AI infrastructure, rather than paying cycle-top prices for growth that may prove unsustainable. For Lumentum's shareholders, the all-stock structure adds another layer of uncertainty — the value of the acquisition premium they ultimately receive will depend on Marvell's stock price at the time the deal closes.
Meanwhile, integrating Marvell's signal processing electronics and optical modules with Lumentum's lasers and other key optical components could trigger lengthy antitrust reviews. Jennifer Rie, a senior litigation analyst at Industry Research, said that while the two companies are likely to obtain regulatory approval, possibly with remedies attached, "China is the wild card." She noted that China's merger control authority is the primary antitrust and timeline risk for the deal.
Chinese regulatory reviews have previously derailed multiple transactions. Qualcomm (QCOM.US) abandoned its $44 billion acquisition of NXP Semiconductors (NXPI.US) in 2018; Intel (INTC.US) cancelled its $5.4 billion acquisition of Tower Semiconductor in 2023 after failing to secure Beijing's approval. Broadcom (AVGO.US)'s $69 billion acquisition of VMware also went through months of uncertainty before receiving conditional approval just days before a key deadline.